ClinicalTrials.gg
Not yet recruitingNCT07849153Updated Sep 30, 2026

An Early Feasibility Study of the BioJet™ Oral Biotherapeutic Delivery System for Administration of Therapeutic Agents in Healthy Participants

A Phase 1 interventional study of Hadlima® and Hadlima® in Healthy Subjects, sponsored by Biora Therapeutics, Inc.. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Biora Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is testing the BioJet™ oral device, a capsule-based method of delivering medicine by mouth, in healthy adult volunteers. Participants will be randomly assigned to one of three groups and will receive a single dose of the study treatment.

The purpose of the study is to compare Hadlima® given through the BioJet™ device with Hadlima® given by a SC injection under the skin. Researchers will evaluate how safe and well tolerated the treatments are, how the body processes the medicine, and whether the body's immune system responds to it.

Approximately 30 healthy adults will take part in this study.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Biora Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between ≥ 18.0 and ≤ 32.0 kg/m2 and weight ≥ 50 kg
  • Not pregnant or breastfeeding, or willing to cease breastfeeding.
  • Woman of (WOCBP) or fertile man agrees to use an acceptable method of from the start of Screening until 5 months after the last dose of IP.
  • Males must agree to not donate sperm from the first dose of IP until at least 5 months after the last dose of IP.
  • WOCBP must agree to not donate ova from the first dose of IP until at least 5 months after the last dose of IP.
  • Nonsmoker. Participants who smoke ≤ 5 cigarettes or equivalent (e.g., cigars, vaping, nicotine patches) per week may be included in the study at the discretion of the Investigator or designee if they agree to abstain for 72 hours before dosing through discharge from inpatient period.

Exclusion criteria

Exclusion Criteria:

  • History of chronic inflammatory or disease requiring therapy.
  • History or presence of any medical condition, including:

    1. Dysphagia, achalasia, or swallowing disorders, including difficulty in swallowing oral medication.
    2. Zenker's diverticulum.
    3. Severe motility disorders such as gastroparesis (delayed gastric emptying) or slow intestinal transit including but not limited to significant gastroesophageal reflux disease, or irritable bowel syndrome under care of a physician.
    4. Gastrointestinal (GI) diverticular disease.
    5. Gastric, small bowel, and/or colonic resections, strictures, and/or obstructions.
    6. History of inflammatory bowel disease including Crohn's disease or ulcerative colitis.
    7. Gastrointestinal surgery (e.g., gastrectomy, laparoscopic banding, Roux-en-Y).
    8. Radiation or chemotherapy-induced enteritis.
    9. Abdominal or pelvic surgery that could impair GI transit per the opinion of the Investigator (history of appendectomy or cholecystectomy are permitted).
    10. Symptomatic hiatal hernia.
    11. Known history of bezoars.
    12. Recent history of peptic ulcer disease within 6 months.
    13. History of cardiovascular, hepatic, renal, pulmonary, GI, neurologic, hematologic, endocrine, psychiatric, or autoimmune disease.
    14. Any significant skin condition or extensive tattoos of the lower abdomen that is likely to impede SC injection or injection-site assessment.
  • Evidence of active or latent TB, including:

    • Positive TB screening test (Interferon-Gamma Release Assay [IGRA]),
    • History of untreated or inadequately treated latent or active TB.
  • History of , except adequately treated non-melanoma skin cancer.
  • Use of systemic , immunosuppressants, or immunomodulators within 7 days or 5 half-lives of the drug (whichever is longer) prior to dosing.
  • History of demyelinating disease (e.g., multiple sclerosis, optic neuritis).
  • History of congestive heart failure or clinically significant cardiac disease.
  • Positive drug or alcohol screening test.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Hadlima® Group 1

    Drug: Hadlima®

  • Active comparator
    Hadlima® Group 2

    Drug: Hadlima®

  • Active comparator
    Hadlima® Group 3

    Drug: Hadlima®

Interventions

  • DrugHadlima®

    Route of administration: via BioJet™ device oral capsule Dose: 30 mg

  • DrugHadlima®

    Route of administration: by SC injection Dose: 20 mg

  • DrugHadlima®

    Route of administration: by SC injection Dose: 40 mg

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs

    Time frame: From Day 1 to day 30 (EOT visit)

  2. Incidence of SAEs

    Time frame: From Day 1 to day 30 (EOT visit)

  3. Number of participants with abnormal vital signs

    Time frame: Days 1, 2,3,8,15 and day 30 (EOT visit)

  4. Number of participants with abnormal Physical examination findings

    Time frame: From Day 1 to day 30 (EOT visit)

  5. Number of participants with abnormal ECG readings

    Time frame: Days 1, 2 and Day 3

  6. Number of participants with abnormal Laboratory findings

    Time frame: Days 1,3,8,15 and Day 30 (EOT visit)

Secondary outcomes

  1. Plasma PK parameters- Cmax (maximum serum concentration)

    Time frame: Days 1,2,3,4,6,8,15 and Day 30 (EOT visit)

  2. Plasma PK parameters- Tmax (time to maximum serum concentration)

    Time frame: Days 1,2,3,4,6,8,15 and Day 30 (EOT visit)

  3. Plasma PK parameters- AUC0-last (area under the concentration-time curve from zero to the last quantifiable concentration)

    Time frame: Days 1,2,3,4,6,8,15 and Day 30 (EOT visit)

  4. Plasma PK parameters- AUC0-inf (area under the concentration-time curve from zero to infinity)

    Time frame: Days 1,2,3,4,6,8,15 and Day 30 (EOT visit)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2027, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Feb 15, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07849153
Lead sponsor
Biora Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

James Connell, Dr.
principal investigator · CMAX Clinical Research Pty Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion